JTO Clinical and Research Reports (Sep 2023)

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing

  • Takamasa Koga, MD, PhD,
  • Junichi Soh, MD, PhD,
  • Akira Hamada, MD, PhD,
  • Yuki Miyano, MS,
  • Toshio Fujino, MD, PhD,
  • Keiko Obata,
  • Shuta Ohara, MD, PhD,
  • Masaya Nishino, MD, PhD,
  • Masato Chiba, MD, PhD,
  • Masaki Shimoji, MD, PhD,
  • Toshiki Takemoto, MD, PhD,
  • Kenichi Suda, MD, PhD,
  • Kazuko Sakai, MD, PhD,
  • Hidenori Sato, PhD,
  • Tetsuya Mitsudomi, MD, PhD

Journal volume & issue
Vol. 4, no. 9
p. 100554

Abstract

Read online

Introduction: Lung tumor organoids (LTOs) have attracted attention as in vitro preclinical models; however, their clinical and experimental applications have not been fully established. Methods: We attempted to establish LTOs from resected specimens of patients with lung cancer who underwent lung resection. Clinicopathologic characteristics related to the establishment of LTOs were evaluated. Histologic assessment and genetic analysis were conducted for both LTOs and their parental tumors. Organoid-derived xenografts were generated in immunocompetent mice. Drug sensitivity was assessed using cell proliferation assays. Results: We established 53 LTOs from 79 lung cancer samples, including 10 long-term culture models. The establishment rate was significantly lower in squamous cell carcinomas than in other histologic types (48% versus 75%, p = 0.034). Histologic similarities were confirmed among LTOs, the parental tumors, and organoid-derived xenografts. Seven mutations, including two EGFR L858R and one EGFR exon 20 H773delinsYNPY mutations, were detected in both LTO and parental tumors; the other four mutations were detected in either LTO or parental tumors. The extensive culture ability of LTO (passaged >10 times) correlated with poor patient prognosis. LTO9 cells harboring EGFR H773delinsYNPY were sensitive to osimertinib. The parental patient, who had new metastatic lesions, was treated with osimertinib and exhibited a remarkable response. Conclusions: The establishment and growth rates of LTOs were associated with the histologic subtype and tumor size. LTOs derived from resected specimens have become preclinical models that can be used to predict drug responses and accelerate the development of treatment strategies for patients with rare mutations.

Keywords